Section 21 Ophthalmological Preparations

Azithromycin eye drops

Application submitted by International Council of Ophthalmology
1. Summary statement of the proposal for inclusion, change or deletion

We propose the inclusion of topical azithromycin eye drops. Trachoma, a chronic keratoconjunctivitis caused by recurrent infection from C. trachomatis, is the leading cause of infectious blindness worldwide.\(^1\) It is estimated that 40 million people worldwide have active trachoma, with 8.2 million of them having trichiasis.\(^1\) Blinding trachoma is thought to be endemic in over 50 countries in Africa, the Middle East, Asia, Latin America and the Western Pacific.\(^1\) WHO estimates from 2002 suggested that 1.3 million people were blind from trachoma, and a further 1.8 million were thought to be suffering from low vision due to this disease.\(^1\) In areas where trachoma is endemic, a large portion of the additional 1.9 million cases of blindness due to corneal opacities are also thought to likely be due to trachoma.\(^1\)

Although blindness from trachoma is irreversible, it can be prevented.\(^1\) The Alliance for Global Elimination of Blinding Trachoma by 2020, established by the WHO in 1997, recommends the SAFE strategy for trachoma control - surgery for trichiasis, antibiotics to treat C. trachomatis infection; facial cleanliness through personal hygiene; environmental improvement with education and improved local economy.\(^1\) The traditional antibiotic strategy for the treatment of trachoma was tetracycline ointment, but more recently the strategy recommended by the WHO was a single dose of oral azithromycin.\(^2\) However, there is a risk that the dose of oral azithromycin initially planned for the campaign against trachoma might be used to treat other systemic infections. As a result, azithromycin could be diverted away from its initial target, those exposed to trachoma.\(^2\) Additionally, it has been suggested that inappropriate use of oral azithromycin could modify the bacterial ecology of strains responsible for systemic infections.\(^2\) The side effects of systemic azithromycin administration must also be taken into account. Azithromycin 1.5% eye drops were developed as an alternative, and have been shown to be just as efficient as oral azithromycin for the treatment of trachoma.\(^2\)

2. Name of the focal point in WHO submitting or supporting the application (where relevant)

Ivo Kocur

3. Name of the organization(s) consulted and/or supporting the application

International Council of Ophthalmology

4. International Nonproprietary Name (INN, generic name) of the medicine

Azithromycin

5. Formulation proposed for inclusion; including adult and paediatric (if appropriate)

Topical azithromycin 1.5% eye drops

6. International availability - sources, if possible manufacturers and trade names

Azithromycin 1.5% eye drops are available under the name Azyter in the UK. In the US, azithromycin 1% drops are available under the name Azasite. It is also available in Western Europe (France, Spain, Italy, Germany, etc.), in North Africa (Morocco, Algeria, Tunisia),
Francophone Africa (Mauritania, Mali, Niger, Senegal, Cameroon, Cote d'Ivoire, Burkina Faso, Burundi, Benin, Togo, Madagascar, etc.), in Asia (Viet Nam, Indonesia, etc.). It is also registered in Mexico, Argentina and Colombia. In several studies of azithromycin for the treatment of trachoma in developing countries, Azyter eye drops have been used.

7. Whether listing is requested as an individual medicine or as an example of a therapeutic group

Individual medicine

8. Information supporting the public health relevance (epidemiological information on disease burden, assessment of current use, target population)

Trachoma, a chronic keratoconjunctivitis caused by recurrent infection from C. trachomatis, is the leading cause of infectious blindness worldwide. It is estimated that 40 million people worldwide have active trachoma, with 8.2 million of them having trichiasis. Blinding trachoma is thought to be endemic in over 50 countries in Africa, the Middle East, Asia, Latin America and the Western Pacific. WHO estimates from 2002 suggested that 1.3 million people were blind from trachoma, and a further 1.8 million were thought to be suffering from low vision due to this disease. In areas where trachoma is endemic, a large portion of the additional 1.9 million cases of blindness due to corneal opacities are also thought to likely be due to trachoma.

Although blindness from trachoma is irreversible, it can be prevented. The traditional antibiotic strategy for the treatment of trachoma was tetracycline ointment, but more recently the strategy recommended by the WHO was a single dose of oral azithromycin. However, there is a risk that the dose of oral azithromycin initially planned for the campaign against trachoma might be used to treat other systemic infections. As a result, azithromycin could be diverted away from its initial target, those exposed to trachoma. Additionally, it has been suggested that inappropriate use of oral azithromycin could modify the bacterial ecology of strains responsible for systemic infections. Azithromycin 1.5% eye drops were developed as an alternative, and have been shown to be just as efficient as oral azithromycin for the treatment of trachoma.

9. Treatment details (dosage regimen, duration; reference to existing WHO and other clinical guidelines; need for special diagnostics, treatment or monitoring facilities and skills)

One drop in each eye twice a day, morning and evening, for three days.

10. Summary of comparative effectiveness in a variety of clinical settings:

"A randomised, controlled, double-masked, double-dummy, non-inferiority explanatory study including 670 children from Guinea Conakry and Pakistan was conducted. Three groups received either: azithromycin 1.5% eye drops twice daily for 2 days, for 3 days or azithromycin single 20 mg/kg oral dose."

"Cure rate in per protocol set was as follows: 93.0%, 96.3% and 96.6% in 2-day group, 3-day group, and oral treatment group, respectively. Azithromycin 1.5% groups were non-inferior to oral azithromycin. The intend to treat (ITT) analysis supported the results. Clinical re-emergence rate was low: 4.2%."
In the per protocol set, cure in both eyes was observed for 91.5%, 93.7% and 95.0% of patients. Azithromycin 1.5% for 2 or 3 days was non-inferior to oral azithromycin.

Only 4.2% of patients with cure at day 30 had clinical re-emergence of trachoma in either eye at day 60: 4.9%, 4.0%, and 3.6% in the 2-day, 3-day, and oral treatment groups, respectively. There were no significant differences between the groups with respect to trachoma re-emergence (p>0.545).

All three treatments markedly reduced the trachomatous grading on days 30 and 60. There were no significant differences between the treatment groups with respect to trachomatous grading (p>0.170).

The authors concluded that "In active trachoma, azithromycin eye drops twice daily for 2 or 3 days are as efficient as the WHO's reference treatment and represent an innovative alternative to oral azithromycin.

In February 2008, a program was undertaken to treat the entire population of the Kolofata Health District in Cameroon (115,274 residents) with azithromycin 1.5% eye drops donated by Thea Laboratories. A total of 51,659 adults and 59,681 children <15 years old were treated.

The prevalence of follicular trachomatous inflammation (TF) in the study sample was estimated to be 24 (95% CI 20.7 to 27.5)% before treatment and 5.8 (95% CI 4.1 to 8)% after treatment (Table 1). The prevalence of TF/ intense trachomatous inflammation (TI) was estimated to be 7.5 (95% CI 5.7 to 10)% before treatment and 0.5 (95% CI 0.13 to 1.6)% after treatment (table 3). The prevalence of active forms (TF + TF/TI) was estimated to be 31.5 (95% CI 26.4 to 37.5)% before treatment and 6.3 (95% CI 4.5 to 8.6)% after treatment (table 3). The OR for TF before and after treatment was 5.1 (range 4.2-6.2). The OR was 14 (range 8.1-24) for TI forms and 6.7 (range 5.6e8.1) for TF + TF/TI forms.

During the second round of treatment 105,802 people (45,288 adults and 60,514 children) received the full 6-dose treatment of azithromycin eye drops. In addition, 41,376 doses were administered to others who did not complete the full 6-dose treatment i.e. to people who were absent during at least one of the treatment administration visit.

"One year after two rounds of topical treatment, prevalence dropped to 3.1% (95%CI 2.0–4.9) (p<0.0001), a decrease of 90%. "The prevalence of TF decreased significantly (p=0.0001) to 3.1% one year after the second round of treatment. The prevalence of TI disappeared after two annual treatments (0% after second treatment (p = 0.0005))."

11. Summary of comparative evidence on safety:

"A randomised, controlled, double-masked, double-dummy, non-inferiority explanatory study including 670 children from Guinea Conakry and Pakistan was conducted. "Three groups
received either: azithromycin 1.5% eye drops twice daily for 2 days, for 3 days or azithromycin single 20 mg/kg oral dose.\textsuperscript{2}

"Ocular adverse events were reported in 10.8%, 8.9% and 13.1% of patients in the 2-day, 3-day and oral treatment groups, respectively. Systemic AEs events were reported in 2.6%, 10.2% and 9.0% of patients. None of the adverse events were treatment-related events. One patient (3-day group) had a serious unrelated adverse events (death due to head injury).

The most frequent unrelated ocular AE was an endemic tropical form of allergic vernal conjunctivitis occurring in 4-5% of patients in each group. There were no notable differences between the three groups.

Difficulty to instil eye drops was reported in 1–4% of patients in each group. Crying during instillation was reported in 7–8% of patients in each treatment group. There were no significant differences between the groups.\textsuperscript{2}

In February 2008, a program was undertaken to treat the entire population of the Kolofata Health District in Cameroon (115,274 residents) with azithromycin 1.5% eye drops donated by Thea Laboratories.\textsuperscript{3} A total of 111,340 people (51,659 adults and 59,681 children <15 years old) and 105,802 people (45,288 adults and 60,514 children) were treated in the first and second rounds of treatment, respectively.\textsuperscript{3}

"Questionnaires concerning any side effects of treatment were administered by ophthalmology nurses during daily visits to assigned villages. Minor complaints were recorded (blurred vision lasting several minutes following instillation of eye drops or transient burning sensation in the eyes).\textsuperscript{3} "The few complaints recorded were local and brief (blurred vision lasting several minutes following instillation of eye drops or transient burning sensation in the eyes).\textsuperscript{4} "No adult requested that treatment for themselves or their children be interrupted. There were no reported serious or systemic side effects.\textsuperscript{3}

12. Summary of available data on comparative cost\textsuperscript{**} and cost-effectiveness within the pharmacological class or therapeutic group:

Comparative cost-effectiveness data on topical azithromycin 1.5% eye drops is not readily available. However, previous administrations of azithromycin 1.5% in large quantities have been supported by donations from Thea pharmaceuticals.

13. Summary of regulatory status of the medicine (in country of origin, and preferably in other countries as well)

Azithromycin ophthalmic 1% solution (Azasite\textsuperscript{®}) was approved by the US FDA in 2007. Topical azithromycin 1.5% solution is registered in Europe and in a number of African countries (as mentioned previously in section 6).

"Overall conclusion

Based on the review of the clinical data on efficacy and safety the RMS considers that the variation application NL/H/0855/001/II/010 for Azyter (azithromycin), in the treatment of local antibacterial treatment of conjunctivitis caused by susceptible strains: purulent bacterial conjunctivitis and trachomatous conjunctivitis caused by Chlamydia trachomatis, in adults and children with the extension to children of 0 to 2 years of age (purulent bacterial conjunctivitis) and the extension to children of 0 to 1 year of age (trachomatous conjunctivitis) is approvable.

15. Proposed (new/adapted) text for the WHO Model Formulary

1. NAME OF THE MEDICINAL PRODUCT

Azyter 15 mg/g, eye drops, solution in single-dose container

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each gram of solution contains 15 mg of azithromycin dihydrate equivalent to 14.3 mg of azithromycin.

One single-dose container of 250 mg solution contains 3.75 milligrams of azithromycin dihydrate.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Eye drops, solution in single-dose container.

Clear, colourless to slightly yellow, oily liquid.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

AZYTER 15 mg/g, eye drops, solution in single-dose container is indicated for the local antibacterial curative treatment of conjunctivitis caused by susceptible strains (see sections 4.4 and 5.1):

- Purulent bacterial conjunctivitis, in children (aged from birth to 17 years) and adults.
- Trachomatous conjunctivitis caused by Chlamydia trachomatis, in children (aged from birth to 17 years) and adults (see section 4.4 “Use in neonates”).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

4.2 Posology and method of administration
Posology

Adult population
Instil one drop in the conjunctival fornix twice a day, morning and evening, during three days.
It is unnecessary to prolong treatment beyond three days.
Adherence to the dosing regimen is important for the success of treatment.

Elderly patients
No dose adjustment is necessary.

Paediatric population
No dose adjustment is necessary (see section 4.4 and 5.1).

Method of administration
Ocular use.
The patient should be advised to:
- thoroughly wash hands before and after the instillation,
- avoid touching the eye or eyelids with the dropper tip of the single-dose container,
- discard the single-dose container after use, and not keep it for subsequent use.

4.3 Contraindications
Hypersensitivity to azithromycin, to any other macrolide or to the excipient listed in section 6.1.

4.4 Special warnings and precautions for use
The eye drops solution should not be injected or be swallowed.
The eye drops solution should not be used for peri- or intra-ocular injection.
In the event of an allergic reaction, the treatment should be discontinued.
The patient should be informed that it is not necessary to continue to instil the eye drops solution after the end of treatment on the third day, even if residual signs of bacterial conjunctivitis remain.
Symptomatic relief occurs generally within 3 days. If there are no signs of improvement after 3 days, diagnosis should be reconsidered.
Contact lenses should not be worn by patients with bacterial conjunctivitis.
With the systemic use of azithromycin cases of fulminant hepatitis potentially leading to life-threatening liver failure have been reported. In ophthalmic use, this risk is not relevant since systemic exposure to the active ingredient is negligible (see section 5.2).

**Paediatric population**

Regarding the treatment of trachomatous conjunctivitis, comparative safety and efficacy studies have not been performed with Azyter 15 mg/g eye drops in children younger than one year, but there are no known safety concerns or differences in disease process to exclude its use in children less than one year old in this indication taking into account clinical experience in children older than one year of age in the treatment of trachomatous conjunctivitis and considering Azyter experience in children from birth in the treatment of purulent bacterial conjunctivitis

**Use in neonates**

Based on the international consensus on diseases involving the eye and genital tractus and susceptible to be transmitted to new-borns, non-trachomatous conjunctivitis caused by *Chlamydia trachomatis* and conjunctivitis caused by *Neisseria gonorrhoeae* require a systemic treatment.

In neonates and infants below the age of 3 months systemic infection (eg pneumonia, bacteremia) due to *Chlamydia trachomatis* may accompany conjunctivitis. In case of suspicion, systemic treatment is required.

This treatment is not intended to be used as prophylaxis for bacterial conjunctivitis in newborn infants.

**4.5 Interaction with other medicinal products and other forms of interaction**

No specific interaction study has been performed with Azyter.

In view of the absence of detectable concentrations of azithromycin in the plasma during the administration of Azyter by ocular instillation (see section 5.2), none of the interactions with other medicinal products described for orally administered azithromycin is expected with use of the eye drops solution.

In the event of concomitant treatment with another eye drops solution, an interval of 15 minutes should be respected between instillation of the two solutions. Azyter should be instilled last.

**4.6 Fertility, pregnancy and lactation**

**Pregnancy**

No effect on pregnancy is anticipated, since systemic exposure to azithromycin is negligible.

AZYTER can be used during pregnancy.
Breastfeeding

Limited data indicate that azithromycin is excreted in breast milk, but, considering the low dose and the low systemic availability, the doses taken by the new-born are negligible. Consequently, breast feeding is possible during the treatment.

Fertility

Animal data do not suggest an effect of the treatment of azithromycin on male and female fertility. Human data are lacking. However, no effect on fertility is anticipated, since systemic exposure to azithromycin is negligible.

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed.

Vision may be transiently blurred after instillation. In this case, the patient should be advised to avoid driving or using machines until normal vision has been re-established.

4.8 Undesirable effects

During clinical trials and according to post-marketing safety data on Azyter eye drops solution, the following treatment-related signs and symptoms were reported:

Immune system disorders

Uncommon (≥1/1000, <1/100)
Angioedema*, hypersensitivity.

Eye disorders

Very common (≥1/10)
Ocular discomfort (pruritus, burning, stinging) upon instillation.

Common (≥1/100, <1/10)
Blurred vision, sticky eye sensation, foreign body sensation upon instillation.

Uncommon (≥1/1000, <1/100)
Conjunctivitis*, allergic conjunctivitis*, keratitis*, eczema eyelids*, eyelid oedema*, eye allergy*, conjunctival hyperemia, lacrimation increased upon instillation, erythema of the eyelid.

* adverse event has not been observed during clinical studies with Azyter. Inclusion of adverse event is based on post-marketing data. The frequency has been assigned based on 3/X, with X representing the total sample size summed up across all relevant clinical trials and studies, which is 3/879 resulting in “uncommon”.

Paediatric population

In paediatric clinical trials, the safety profile was similar to that in adults and no new adverse events were identified. The safety profiles in the different paediatric subsets were also similar (see Section 5.1).

4.9 Overdose
The total amount of azithromycin in a single-dose container, containing a sufficient quantity for treating both eyes, is too small to induce adverse effects after inadvertent intravenous or oral administration.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: antibiotics, ATC code: S01AA26

Mode of action

Azithromycin is a second-generation macrolide antibiotic belonging to the azalide group.

It inhibits the synthesis of bacterial proteins by binding to the 50S ribosomal subunit and preventing peptide translocation.

Mechanism of resistance

Generally, the resistance of different bacterial species to macrolides has been reported to occur by three mechanisms associated with target site alteration, antibiotic modification, or altered antibiotic transport (efflux). Various efflux pump systems have been described in bacteria. An important efflux system in streptococci is conferred by the \textit{mef} genes and results in a macrolide-restricted resistance (M phenotype). Target modification is controlled by \textit{erm} encoded methylases (MLS\textsubscript{B} phenotype) and results in cross-resistance to several classes of antibiotics (see below).


Constitutive mutants in inducibly resistant strains with \textit{erm}(A) or \textit{erm}(C) can be selected \textit{in vitro} at low frequencies \(\sim 10^{-7}\) cfu in the presence of azithromycin.

Breakpoints

The list of micro-organisms presented hereafter has been targeted to the indications (see section 4.1.).

Note that the breakpoints and \textit{in-vitro} activity spectrum presented hereafter are those applicable to systemic use. These breakpoints may not be applicable to topical ocular application of the drug product due to the local concentrations that are reached and the local physicochemical conditions that may influence the overall activity of the agent at the site of application.

According to the EUCAST (European Committee on Antimicrobial Susceptibility Testing) the following breakpoints have been defined for azithromycin:
- *Haemophilus influenzae*: \( S \leq 0.12 \text{ mg/l} \) and \( R > 4 \text{ mg/l} \)
- *Moraxella catarrhalis*: \( S \leq 0.5 \text{ mg/l} \) and \( R > 0.5 \text{ mg/l} \)
- *Neisseria gonorrhoeae*: \( S \leq 0.25 \text{ mg/l} \) and \( R > 0.5 \text{ mg/l} \)
- *Staphylococcus spp*:\*: \( S \leq 1.0 \text{ mg/l} \) and \( R > 2.0 \text{ mg/l} \)
- *Streptococcus pneumoniae*: \( S \leq 0.25 \text{ mg/l} \) and \( R > 0.5 \text{ mg/l} \)
- *Streptococcus A, B, C, G*: \( S \leq 0.25 \text{ mg/l} \) and \( R > 0.5 \text{ mg/l} \)
*\( \text{spp includes all the species of the genus} \)

For other species, EUCAST allows that erythromycin can be used to determine the susceptibility of the listed bacteria to azithromycin.

The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence is such that the utility of the agent in at least some types of infections is questionable.

**Table: Antibacterial spectrum of azithromycin for bacterial species relevant to the indications**

<table>
<thead>
<tr>
<th>Commonly susceptible species</th>
<th>Species for which acquired resistance may be a problem</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aerobic Gram-negative</td>
<td><em>Staphylococcus aureus</em> (methicillin resistant and methicillin susceptible)</td>
</tr>
<tr>
<td><em>Moraxella (Branhamella) catarrhalis</em></td>
<td><em>Staphylococcus</em>, coagulase negative (methicillin resistant and methicillin susceptible)</td>
</tr>
<tr>
<td><em>Neisseria gonorrhoeae</em></td>
<td><em>Streptococcus pneumoniae</em></td>
</tr>
<tr>
<td><em>Haemophilus influenzae</em></td>
<td><em>Streptococcus A, B, C, G</em></td>
</tr>
<tr>
<td><em>Haemophilus parainfluenzae</em></td>
<td><em>Streptococcus pneumoniae</em></td>
</tr>
<tr>
<td>Other micro-organisms</td>
<td></td>
</tr>
<tr>
<td><em>Chlamydia trachomatis</em></td>
<td></td>
</tr>
</tbody>
</table>

\*\( \text{spp includes all the species of the genus} \)
<table>
<thead>
<tr>
<th><strong>Streptococcus pyogenes</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Streptococci viridans</strong></td>
</tr>
<tr>
<td><strong>Streptococcus agalactiae</strong></td>
</tr>
<tr>
<td><strong>Streptococcus group G</strong></td>
</tr>
</tbody>
</table>

**Inherently resistant organisms**

- Aerobic Gram positive
- **Corynebacterium spp.**
- **Enterococcus faecium**
- **Aerobic Gram-negative**
- **Pseudomonas aeruginosa**
- **Acinetobacter**
- **Enterobacteriaceae**

* Clinical effectiveness is demonstrated by sensitive isolated organisms for approved indications.

$ $ Natural intermediate susceptibility

1 Conjunctivitis caused by *Neisseria gonorrhoeae* require a systemic treatment (see section 4.4).

**Information from clinical trials**

- Trachomatous conjunctivitis caused by *Chlamydia trachomatis*. Azyter was evaluated in a two-month, randomised, double-masked study comparing Azyter with a single oral dose of azithromycin for the treatment of trachoma in 670 children (1-10 years). The primary efficacy variable was the clinical cure at Day 60, *i.e.* a grade TF0 (simplified WHO grading scale). At Day 60, clinical cure rate of Azyter instilled twice daily for 3 days (96.3%) was non-inferior to that of oral azithromycin (96.6%).

The clinical efficacy of Azyter (instilled twice daily for 3 days) in mass curative and prophylactic treatment of trachoma in an entire population (from birth) in a northern Cameroon district (112 000 subjects) was assessed in a multicentre, open-label, single-arm, phase IV study. Three annual treatment periods were performed. The primary efficacy endpoint was the prevalence of active trachoma, *i.e.* trachomatous inflammation-
follicular or trachomatous inflammation-intense (TF+TI0 or TF+TI+). For analysis, clinical assessment of trachoma was performed each year in a sample of 2400 children aged ≥1 and < 10 years old selected using a random cluster sampling. The prevalence of active trachoma (TF+TI0 or TF+TI+) was 31.1% at Year 0 (before Azyter instillations) and decreased to 6.3% at Year 1, 3.1% at Year 2 and 3.1% at Year 3.

In the whole population, there was no serious adverse event in relation with the study drug.

- Purulent bacterial conjunctivitis. Azyter was evaluated in a randomised, investigator-masked study comparing Azyter, instilled twice daily for 3 days, with tobramycin 0.3% eye drops, instilled every two hours for 2 days then four times daily for 5 days, for the treatment of purulent bacterial conjunctivitis in 1043 patients (ITT set), including 109 children up to the age of 11 years from whom 5 were newborn infants (0 to 27 days) and 38 infants and toddlers (28 days to 23 months of age). In the Per Protocol set (n=471), there were no newborns and only 16 infants and toddlers. The clinical study was performed in different areas in Europe, North Africa, and India. The primary efficacy variable was the clinical cure at Day 9 in the PP set, defined as a score of 0 for both the bulbar conjunctival injection and the purulent discharge. At Day 9, clinical cure rate of Azyter (87.8%) was non-inferior to that of tobramycin (89.4%). Microbiological resolution rate of Azyter was comparable to that of tobramycin.

**Paediatric population**

The efficacy and safety of Azyter in paediatric patients ≤ 18 years of age was demonstrated in a randomised, investigator-masked study compared with tobramycin in 282 analysed patients diagnosed with purulent bacterial conjunctivitis (including 148 patients in the subgroup 0 day - < 24 months). Patients received either Azyter, instilled twice daily for 3 days or tobramycin 0.3% eye drops, instilled every two hours for 2 days then four times daily for 5 days. The primary efficacy endpoint was the clinical cure in the worse eye on D3 for patients with D0 positive bacterial cultures. Clinical cure in the worse eye on D3 was demonstrated to be significantly superior for Azyter (47%) than for tobramycin (28%). At D7, 89% of patients treated with Azyter were cured versus 78% with tobramycin. No statistical difference was found between treatment groups for the bacteriological resolution at D7.

Azyter (instilled twice daily for 3 days) was well-tolerated in all age groups in this large study in paediatric population. The events observed in paediatric subjects were a subset of those previously observed in adults; no new adverse events were identified in paediatric subjects. Furthermore, no age-related patterns of clinical concern were evident. The short duration of Azithromycin 1.5% treatment, the low number of instillations needed and the easiness of instilling drops in children were appreciated by both children and parents.

### 5.2 Pharmacokinetic properties
Azithromycin was not detected in the blood of patients with bacterial conjunctivitis after instillation of Azyter at the recommended dose (detection limit: 0.0002 µg/mL of plasma).

**Paediatric population**

Pharmacokinetic studies have only been performed in adults.

### 5.3 Preclinical safety data

In animals, azithromycin caused reversible phospholipidosis. This effect was seen after oral exposures which were about 300 times in excess of the maximum human exposure after ocular administration indicating little relevance to clinical use.

Electrophysiological investigations have shown that azithromycin prolongs the QT interval.

**Carcinogenic potential**

Long-term studies in animals have not been performed to evaluate carcinogenic potential.

**Mutagenic potential**

There was no evidence of a potential for genetic and chromosome mutations in *in vivo* and *in vitro* test models.

**Reproductive toxicity**

No teratogenic effects were observed in embryotoxicity studies in rats after oral administration of azithromycin. In rats, azithromycin dosages of 100 and 200 mg/kg body weight/day led to mild retardations in fetal ossification and in maternal weight gain. In peri- and postnatal studies in rats, mild retardations following treatment with 50 mg/kg/day azithromycin and above were observed. These effects were seen after oral administration at exposures which were about 1000 times in excess of the maximum human exposures after ocular administration. Because of the high safety margin, these findings do not point to a relevant risk for human reproduction.

**Ocular toxicity**

Ocular administration of Azyter eye drops to animals twice or three times a day during 28 days did not demonstrate any local or systemic toxic effect.

### 6. PHARMACEUTICAL PARTICULARS

#### 6.1 List of excipients

Triglycerides, medium-chain.

#### 6.2 Incompatibilities
Not applicable.

6.3 Shelf life

18 months

After opening of the single-dose container, the eye drops, solution should be used immediately.

Discard the opened single-dose container immediately after first use.

6.4 Special precautions for storage

Do not store above 25°C.

Keep the single-dose containers in the sachet in order to protect them from light.

6.5 Nature and contents of container

Single-dose low-density polyethylene container, each containing 0.25 g, enclosed in a sachet.

Pack-size: box of six single-dose containers.

6.6 Special precautions for disposal

No special requirements.

References